Stock SR3 STAAR SURGICAL COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

News STAAR Surgical Company Deutsche Boerse AG

Equities

SR3

US8523123052

Market Closed - Deutsche Boerse AG
Other stock markets
 02:05:14 2024-07-12 am EDT 		5-day change 1st Jan Change
43.4 EUR +2.75% Intraday chart for STAAR Surgical Company +9.02% +50.22%
Jun. 21 STAAR Surgical Company Provides Information to the Shareholders CI
Jun. 12 Transcript : STAAR Surgical Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
STAAR Surgical Company Provides Information to the Shareholders
CI
STAAR Surgical : Investor Presentation
PU
Transcript : STAAR Surgical Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM
BTIG Upgrades STAAR Surgical to Buy From Neutral, Price Target is $46
MT
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
BU
Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating
MT
Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating
MT
Staar Surgical: Q1 Earnings Snapshot
AQ
Transcript : STAAR Surgical Company, Q1 2024 Earnings Call, May 07, 2024
STAAR Surgical Company Reports Earnings Results for the First Quarter Ended March 29, 2024
CI
STAAR Surgical Reports First Quarter 2024 Results
BU
STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision
BU
STAAR Surgical Company Reiterates Earnings Guidance for the Fiscal Year 2024
CI
STAAR Surgical Company Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision
CI
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
BU
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
CI
STAAR Surgical to Report First Quarter Results on May 7, 2024
BU
Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating
MT
Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating
MT
STAAR Surgical Shares Jump After Reporting Preliminary Fiscal Q1 Sales
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STAA Stock
  4. SR3 Stock
  5. News STAAR Surgical Company